Lorezepam

# Lorezepam ## Overview - **Classification**: Benzodiazepine; anxiolytic, sedative-hypnotic, anticonvulsant. - **Mechanism**: Potentiates GABA, an inhibitory neurotransmitter, by binding to GABA-A receptors. This increases chloride ion influx, hyperpolarizing neurons and reducing excitability. ## Primary Indications 1. **Anxiety Disorders** - Management of anxiety symptoms. 2. **Insomnia** - Short-term treatment, particularly anxiety-related insomnia. 3. **Status Epilepticus** - Acute treatment of tonic-clonic seizures. 4. **Premedication** - Before surgery or diagnostic procedures (anxiolysis, sedation, amnesia). 5. **Alcohol Withdrawal** - Management of acute symptoms and prevention of delirium tremens. ## Adult Dosing ### Standard Dosing **Anxiety** - **Dose**: **1 mg** to **2 mg** - **Frequency**: **2** to **3 times daily** - **Route**: Oral (PO) - **Duration**: Short-term; re-evaluate therapy regularly. **Insomnia** - **Dose**: **2 mg** to **4 mg** - **Frequency**: Once, at bedtime - **Route**: Oral (PO) **Status Epilepticus** - **Dose**: **4 mg** - **Frequency**: Single dose; may repeat once after **10-15 min** if seizures persist. - **Route**: Intravenous (IV) push - **Maximum**: **8 mg** per 12-hour period. **Premedication** - **Dose**: **0.02 mg/kg** to **0.05 mg/kg** (usually **2 mg** to **4 mg**) - **Frequency**: Single dose, **30-45 min** before procedure. - **Route**: Intravenous (IV) or Intramuscular (IM) **Alcohol Withdrawal** - **Dose**: **1 mg** to **2 mg** - **Frequency**: Every **2** to **6 hours** as needed, based on symptoms. - **Route**: Oral (PO) or Intravenous (IV) ### Dose Adjustments - **Renal Impairment**: No specific dose adjustment needed. Use with caution. - **Hepatic Impairment**: Reduce initial dose by **50%**. Monitor closely for increased sedation. - **Elderly Patients**: Start with lower initial doses (e.g., **0.5 mg** to **1 mg**). Monitor for excessive sedation and falls. ## Pediatric Dosing ### Neonates (0-28 days) - **Status Epilepticus (Off-label)** - **Dose**: **0.05 mg/kg** to **0.1 mg/kg** - **Frequency**: Single dose; may repeat once after **10-15 min** if needed. - **Maximum**: **4 mg/dose** - **Special Notes**: Use IV formulation without benzyl alcohol. Monitor respiratory status. ### Infants (1-12 months) - **Status Epilepticus** - **Dose**: **0.05 mg/kg** to **0.1 mg/kg** - **Frequency**: Single dose; may repeat once after **10-15 min** if needed. - **Maximum**: **4 mg/dose** - **Special Notes**: Monitor respiratory and cardiac function closely. ### Children (1-12 years) - **Status Epilepticus** - **Dose**: **0.05 mg/kg** to **0.1 mg/kg** - **Frequency**: Single dose; may repeat once after **10-15 min** if needed. - **Maximum**: **4 mg/dose** - **Anxiety/Sedation (Off-label)** - **Dose**: **0.025 mg/kg** to **0.05 mg/kg** - **Frequency**: Every **4** to **8 hours** - **Maximum**: **2 mg/dose** (single); **6 mg/day** ### Adolescents (13-18 years) - **Dose**: Generally follows adult dosing guidelines. - **Maximum**: Up to **4 mg/dose** IV for status epilepticus; up to **10 mg/day** oral for anxiety. ## Safety Information ### Contraindications - **Absolute**: Acute narrow-angle glaucoma. - **Absolute**: Severe respiratory insufficiency (e.g., severe COPD, sleep apnea). - **Absolute**: Hypersensitivity to benzodiazepines or any component. - **Absolute**: Concurrent use with **potent CYP3A4 inhibitors** for respiratory depression risk. ### Common Adverse Effects - **Very Common (>10%)**: Sedation, drowsiness, fatigue, weakness. - **Common (1-10%)**: Dizziness, ataxia, blurred vision. - **Common (1-10%)**: Constipation, nausea. - **Serious but Rare**: Respiratory depression, paradoxical excitation, suicidal ideation. - **Serious but Rare**: Anterograde amnesia, withdrawal seizures (abrupt discontinuation). ### Key Drug Interactions - **CNS Depressants (Opioids, Alcohol, Antihistamines)**: Increased risk of profound sedation, respiratory depression, coma, death. Avoid concomitant use or use lower doses. - **Valproate**: May increase lorazepam levels by inhibiting glucuronidation. Consider lorazepam dose reduction. - **Probenecid**: May increase lorazepam levels and prolong its effects. Consider lorazepam dose reduction. - **Theophylline/Aminophylline**: May reduce the sedative effects of lorazepam. ## Monitoring & Follow-up - **Before Treatment**: Assess for underlying respiratory conditions, substance abuse history, mental health. - **During Treatment**: Monitor level of consciousness, respiratory rate, blood pressure, heart rate. - **During Treatment**: Monitor for paradoxical reactions, signs of tolerance or dependence. - **Clinical Signs**: Watch for excessive sedation, unsteadiness, confusion, agitation. - **Clinical Signs**: For IV administration, monitor vital signs every **5-15 min** initially. ## Clinical Pearls - 💡 **Tip 1**: Lorazepam has no active metabolites and is primarily glucuronidated, making it a preferred benzodiazepine in hepatic impairment. - 💡 **Tip 2**: For acute agitation or seizures, IV lorazepam has a rapid onset (**1-5 minutes**) and longer duration than IV diazepam. - 💡 **Tip 3**: Taper slowly when discontinuing chronic use to avoid severe withdrawal symptoms (e.g., seizures, psychosis, rebound anxiety). - 💡 **Tip 4**: Advise patients to avoid driving or operating machinery due to potential impaired alertness and coordination. - 💡 **Tip 5**: Lorazepam is often a first-line agent in acute seizure management due to its efficacy, rapid action, and IV availability. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.